Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2025, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.

Employees

Sector

Pharmaceuticals

Calendar

09-16 Earnings release - Q2 2026

More about the company

Market Cap	23.98M 27.3M 22.3M 20.46M 38.44M 2.63B 39.04M 265M 103M 1.29B 102M 100M 4.47B	P/E 2026 *	-3.51x	P/E 2027 *	-3.75x
Enterprise Value	47.08M 53.6M 43.78M 40.17M 75.48M 5.16B 76.65M 520M 203M 2.54B 201M 197M 8.77B	EV / Sales 2026 *	7.13x	EV / Sales 2027 *	6.65x
Free-Float	95.15%	Yield 2026 *	-	Yield 2027 *	-

07-21	Advicenne's Distal Renal Tubular Acidosis Medicine Secures Reimbursement in Spain	MT
07-16	Advicenne S.A. Reports Sales Results for the First Half of 2026	CI
07-02	UK Regulator Grants 'Unlimited Renewal' of Advicenne's Distal Renal Tubular Acidosis Drug	MT
07-01	Advicenne Announces Unlimited Renewal of Marketing Authorization for Sibnayal in United Kingdom	CI
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne Raises EUR4 Million from Two-tranche Bonds Issuance	MT
06-22	Advicenne S.A. Secures Its Cash Runway to Second Quarter 2027 Through A Bond Financing of A Nominal Amount of Up to EUR 3.8 Million	CI
06-01	Advicenne soars as Likozam secures social security reimbursement
06-01	Advicenne's Likozam added to France's list of reimbursable medicines
05-21	Advicenne S.A. Announces Board Changes	CI
05-06	Investors Can't Get Enough of Chips
04-23	Advicenne S.A. Auditor Raises 'Going Concern' Doubt	CI

07-20	Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain	BU
07-16	Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France	BU
07-01	Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom	BU
06-23	Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8 million	AQ
06-22	Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million	BU

07-20	Le produit phare d'Advicenne remboursé en Espagne
07-20	Advicenne annonce le remboursement de Sibnayal® dans le traitement de l’ATRd en Espagne
07-16	Advicenne : Le chiffre d’affaires net du premier semestre 2026 porté par le remboursement de Sibnayal® et Likozam® en France
07-01	Advicenne annonce le renouvellement illimité de l’Autorisation de Mise sur le Marché de Sibnayal® au Royaume-Uni
06-23	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

Manager	Title	Age	Since
Didier Laurens CEO	Chief Executive Officer	59	2021-05-02
Delphine Dumas CTO	Chief Tech/Sci/R&D Officer	-	2025-08-31
Véronique Leblanc CTO	Chief Tech/Sci/R&D Officer	-	2023-03-31

Advicenne S.A. Stock OTC Markets

Stocks

ADVV.F

FR0013296746

Pharmaceuticals

Valuation: Advicenne S.A.

Latest news : Advicenne S.A.

Analysts' recommendations: Advicenne S.A.

Press Releases: Advicenne S.A.

News in other languages: Advicenne S.A.

Managers and Directors: Advicenne S.A.

Biopharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
André Ulmann BRD	Director/Board Member	-	2017-06-22
Catherine Dunand BRD	Director/Board Member	64	2017-03-08
Charlotte Sibley BRD	Director/Board Member	78	2018-09-19

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADVICENNE S.A.	-.--%	-.--%	-	-	27.3M
REGENERON PHARMACEUTICALS, INC.	+0.63%	-3.06%	+16.50%	-10.12%	66.74B
UCB	+1.23%	+2.80%	+38.09%	+200.66%	53.32B
SAMSUNG BIOLOGICS CO.,LTD.	+10.08%	+51.80%	+51.80%	+51.80%	48.12B
CSL LIMITED	-1.32%	-7.38%	-57.37%	-56.96%	38.25B
BIOGEN INC.	+0.78%	-1.84%	+53.73%	-25.20%	29.85B
INCYTE CORPORATION	+0.84%	+0.36%	+67.62%	+84.46%	23.51B
MODERNA, INC.	-5.17%	-12.54%	+58.33%	-55.63%	21.45B
INNOVENT BIOLOGICS, INC.	-1.21%	+1.12%	+0.90%	+164.17%	19.97B
BRIDGEBIO PHARMA, INC.	+1.31%	+3.24%	+81.47%	+157.97%	16.47B
Average	+0.72%	-0.53%	+34.56%	+56.79%	35.3B
Weighted average by Cap.	+1.48%	+0.11%	+29.07%	+51.17%

	2026 *	2027 *
Net sales	6.6M 7.51M 6.14M 5.63M 10.58M 724M 10.75M 72.89M 28.48M 356M 28.21M 27.6M 1.23B	8M 9.11M 7.44M 6.83M 12.83M 877M 13.03M 88.35M 34.52M 431M 34.19M 33.46M 1.49B
Net income	-6.7M -7.63M -6.23M -5.72M -10.74M -735M -10.91M -73.99M -28.91M -361M -28.64M -28.02M -1.25B	-6.2M -7.06M -5.77M -5.29M -9.94M -680M -10.09M -68.47M -26.75M -334M -26.5M -25.93M -1.16B
Net Debt	23.1M 26.3M 21.48M 19.71M 37.04M 2.53B 37.61M 255M 99.66M 1.25B 98.73M 96.61M 4.31B	29.2M 33.25M 27.16M 24.92M 46.82M 3.2B 47.54M 322M 126M 1.57B 125M 122M 5.44B